It's been a tough yearfor Celgene Corp. (NASDAQ: CELG)investors, but upcoming phase 3 data on luspaterceptfrom Acceleron Pharma (NASDAQ: XLRN)could rekindle interest in Celgene's stock price. Acceleron is expected to report trial results for luspatercept in myelodysplastic syndromes (MDS) and beta thalassemia anytime now, and if the results are positive, Celgene thinks luspatercept could be a multibillion-dollar-per-year blockbuster.
Big News Is Fast Approaching for Celgene
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться